Knockdown of mortalin within the medial prefrontal cortex impairs normal sensorimotor gating

Synapse

Volumn 64, Issue 11, 2010, Pages 808-813

  Gabriele, Nicole ^a   Pontoriero, Giuseppe F ^a   Thomas, Nancy ^a   Shethwala, Shazli K ^a   Pristupa, Zdenek B ^a   Gabriele, Joseph P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Dopamine; Knockdown; Mortalin

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DOPAMINE; HEAT SHOCK PROTEIN 70; MORTALIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE ASSOCIATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PATHOGENESIS; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SENSORY GATING;

ACOUSTIC STIMULATION; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HSP70 HEAT-SHOCK PROTEINS; INTERPERSONAL RELATIONS; MALE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SENSORY GATING; STARTLE REACTION;

EID: 78149472756     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20794     Document Type: Article

References (29)

1. Braff DL, Geyer MA, Swerdlow NR. 2001. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156: 234-258.
2. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, Zahm DS. 2004. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases. Neurotoxicology 25: 101-115.
3. Carter CJ, Pycock CJ. 1978. Lesions of the frontal cortex of the rat: Changes in neurotransmitter systems in sub-cortical regions [proceedings]. Br J Pharmacol 64: 430P.
4. Chong VZ, Costain W, Marriott J, Sindwani S, Knauer DJ, Wang JF, Young LT, MacCrimmon D, Mishra RK. 2004. Differential display polymerase chain reaction reveals increased expression of striatal rat glia-derived nexin following chronic clozapine treatment. Pharmacogenom J 4: 379-387.
5. Del Arco A, Mora F. 2008. Prefrontal cortex-nucleus accumbens interaction: In vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol Biochem Behav 90: 226-235.
6. Deocaris CC, Kaul SC, Wadhwa R. 2009. The versatile stress protein mortalin as a chaperone therapeutic agent. Protein Pept Lett 16: 517-529.
7. Dyck BA, Skoblenick KJ, Castellano JM, Ki K, Thomas N, Mishra RK. 2009. Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse (New York) 63: 662-672.
8. Gabriele J, Thomas N, S NM, Mishra R. 2007. Differential modulation of a 40 kDa catecholamine regulated protein in the core and shell subcompartments of the nucleus accumbens following chronic quinpirole and haloperidol administration in the rat. Synapse (New York, NY) 61: 835-842.
9. Gabriele J, Pontoriero GF, Thomas N, Thomson CA, Skoblenick K, Pristupa ZB, Mishra RK. 2009. Cloning, characterization, and functional studies of a human 40-kDa catecholamine-regulated protein: Implications in central nervous system disorders. Cell Stress & Chaperones 14: 555-567.
10. Gabriele JP, Pontoriero GF, Thomas N, Ferro MA, Mahadevan G, MacCrimmon DJ, Pristupa ZB, Mishra RK. Antipsychotic Drug use is correlated with CRP40/Mortalin mRNA expression in the dorsolateral prefrontal cortex of human postmortem brain specimens. Schizophrenia Res (in press).
11. Gonzalez LE, Rujano M, Tucci S, Paredes D, Silva E, Alba G, Hernandez L. 2000. Medial prefrontal transection enhances social interaction. I. Behavioral studies. Brain Res 887: 7-15.
12. Goto Y, Grace AA. 2005. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nature Neurosci 8: 805-812.
13. Karreman M, Moghaddam B. 1996. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: An effect mediated by ventral tegmental area. J Neurochem 66: 589-598.
14. Ma D, Chan MK, Lockstone HE, Pietsch SR, Jones DN, Cilia J, Hill MD, Robbins MJ, Benzel IM, Umrania Y, Guest PC, Levin Y, Maycox PR, Bahn S. 2009. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res 8: 3284-3297.
15. McLay RN, Freeman SM, Zadina JE. 2001. Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice. Neurotoxicity Res 3: 249-253.
16. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. 2002. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5: 267-271.
17. Mizukoshi E, Suzuki M, Loupatov A, Uruno T, Hayashi H, Misono T, Kaul SC, Wadhwa R, Imamura T. 1999. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin. Biochem J 343(Part 2): 461-466.
18. Sahu NK, Shilakari G, Nayak A, Kohli DV. 2007. Antisense technology: A selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol 8: 291-304.
19. Sams-Dodd F. 1998. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18: 293-304.
20. Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M. 2008. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105: 546-556.
21. Sharan N, Chong VZ, Nair VD, Mishra RK, Hayes RJ, Gardner EL. 2003. Cocaine treatment increases expression of a 40 kDa catecholamine-regulated protein in discrete brain regions. Synapse (New York, NY) 47: 33-44.
22. Stroup TS. 2007. Heterogeneity of treatment effects in schizophrenia. Am J Med 120(4 Suppl 1 ): S26-S31.
23. Swerdlow NR, Caine SB, Geyer MA. 1992. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacology 108: 189-195.
24. Thompson TL, Moss RL. 1995. In vivo stimulated dopaminerelease in the nucleus accumbens: Modulation by the prefrontal cortex. Brain Res 686: 93-98.
25. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG. 2009. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 34: 487-500.
26. Wallace DL, Han MH, Graham DL, Green TA, Vialou V, Iniguez SD, Cao JL, Kirk A, Chakravarty S, Kumar A, Krishnan V, Neve RL, Cooper DC, Bolanos CA, Barrot M, McClung CA, Nestler EJ. 2009. CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nat Neurosci 12: 200-209.
27. Weinberger DR, Berman KF, Daniel DG. 1992. Mesoprefrontal cortical dopaminergic activity and prefrontal hypofunction in schizophrenia. Clin Neuropharmacol 15: 568A-569A.
28. Xu L, Voloboueva LA, Ouyang Y, Emery JF, Giffard RG. 2009. Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces oxidative stress, and protects from focal ischemia. J Cereb Blood Flow Metab 29: 365-374.
29. Zavitsanou K, Cranney J, Richardson R. 1999. Dopamine antagonists in the orbital prefrontal cortex reduce prepulse inhibition of the acoustic startle reflex in the rat. Pharmacol Biochem Behav 63: 55-61.